Expression of EPK in Recurrent Miscarriage

Recurrent Miscarriage Clinical Trial

— EPK-RM  

Official title:

MAP Kinase Signaling Pathways Through ERK and p-ERK Protein in Human Placenta of Women With Recurrent Miscarriage

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02694367
• Other study ID #: ERK
• Status: Completed
• Phase: N/A
• First received: February 24, 2016
• Last updated: February 26, 2016
• Start date: January 2015
• Est. completion date: January 2016

Study information

• Verified date: February 2016
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Egypt: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The present study is based on hypotheses that some as yet unknown genetic factors may result in recurrent miscarriage (RM). Consequently, the main aim of this study was to gain new information about the underlying genetic causes of RM in the Egyptian population and to investigate the expression of ERK and p-ERK protein in human placenta and their corresponding tissue, to assess the significance of MAPK signal pathway in progression of recurrent miscarriage and PI3K-Akt Pathway.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: January 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Gestational age less than 12 weeks.

2. no uterine abnormalities (examined by ultrasonography or hysterosonogram)

3. previous history of RM, defined as two or more consecutive miscarriages

Exclusion Criteria:

1. Gestational age 12 weeks or more.

2. Endocrine etiology like (thyroid dysfunction, and uncontrolled diabetes mellitus).

3. Antiphospholipid syndrome, inherited thrombophilias, alloimmune causes.

4. Uterine anatomic anomalies

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Abortion, Habitual
• Abortion, Spontaneous
• Recurrent Miscarriage

Intervention

Other:
• Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins

Locations

Country	Name	City	State
Egypt	Ahmed Abbas	Assiut	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The levels of ERK and AKT in placenta		48 hours	Yes